During the past decade, Hôpital Nord conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Hôpital Nord" are "Carcinoma" (1 trials), "Intestinal Obstruction" (1 trials), "Multiple Sclerosis, Relapsing-Remitting" (1 trials) and "Peritoneal Neoplasms" (1 trials). Many other conditions were trialed in "Hôpital Nord" in a lesser frequency.

Most popular intervention types in "Hôpital Nord" are "Drug" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "EGb 761® (Tanakan®)" (1 trials), "Lanreotide (microparticle formulation)" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Nord" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Hôpital Nord". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Hôpital Nord, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Nord, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".